Statistics

Total Visits

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)47

Select a period of time:

Number of views in the range

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)27

Views

Views
October 20242
November 20241
December 20241
January 20252
February 20257
March 202514
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore14
United States11
Germany2
 

Top cities views

Views